Literature DB >> 19917329

Epidemiology and natural history of atherosclerotic renovascular disease.

Constantina Chrysochou1, Philip A Kalra.   

Abstract

Atheromatous renovascular disease (ARVD) is increasingly suspected and diagnosed, and it commonly presents to several different clinical specialties. In this review, the epidemiology, risk factors, comorbid disease associations, natural history, and prognosis of ARVD is described. Atheromatous renovascular disease is strongly associated with macrovascular pathology in other important vascular beds, especially the coronary, aortoiliac and iliofemoral circulations, and also with structural and functional heart disease. These clinicopathologic relationships contribute to the high morbidity and mortality associated with the condition. Understanding of the natural history of renal artery stenosis may enable intensified treatment strategies to reduce associated risk and improve patient prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19917329     DOI: 10.1016/j.pcad.2009.09.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  20 in total

1.  Cost-effectiveness of chronic kidney disease mass screening test in Japan.

Authors:  Masahide Kondo; Kunihiro Yamagata; Shu-ling Hoshi; Chie Saito; Koichi Asahi; Toshiki Moriyama; Kazuhiko Tsuruya; Hideaki Yoshida; Kunitoshi Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-12-14       Impact factor: 2.801

2.  Etiology of renal artery stenosis in 2047 patients: a single-center retrospective analysis during a 15-year period in China.

Authors:  M Peng; X-J Jiang; H Dong; Y-B Zou; H-M Zhang; L Song; B Li; Y-J Yang; H-Y Wu; R-L Gao; W-G Zhang; L-S Liu
Journal:  J Hum Hypertens       Date:  2015-05-07       Impact factor: 3.012

3.  Risk factor profile for chronic kidney disease is similar to risk factor profile for small artery disease.

Authors:  Stephen T Turner; Andrew D Rule; Gary L Schwartz; Iftikhar J Kullo; Thomas H Mosley; Clifford R Jack; Sharon L R Kardia; Eric Boerwinkle; Kent R Bailey
Journal:  J Hypertens       Date:  2011-09       Impact factor: 4.844

4.  Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease.

Authors:  Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman
Journal:  Basic Res Cardiol       Date:  2020-01-14       Impact factor: 17.165

5.  Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis.

Authors:  Alejandro R Chade
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-09       Impact factor: 3.619

Review 6.  Darkness at the end of the tunnel: poststenotic kidney injury.

Authors:  Alfonso Eirin; Lilach O Lerman
Journal:  Physiology (Bethesda)       Date:  2013-07

7.  Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension.

Authors:  Lucas Lauder; Sebastian Ewen; Abraham Rami Tzafriri; Elazer Reuven Edelman; Thomas Felix Lüscher; Peter J Blankenstijn; Oliver Dörr; Markus Schlaich; Faisal Sharif; Michiel Voskuil; Thomas Zeller; Christian Ukena; Bruno Scheller; Michael Böhm; Felix Mahfoud
Journal:  EuroIntervention       Date:  2018-05-20       Impact factor: 6.534

8.  Association between herpes zoster and end stage renal disease entrance in chronic kidney disease patients: a population-based cohort study.

Authors:  S-Y Lin; J-H Liu; H-C Yeh; C-L Lin; I-J Tsai; P-C Chen; F-C Sung; Y-F Yang; C-C Huang; D E Morisky; Y-J Chang; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-17       Impact factor: 3.267

Review 9.  Renovascular Hypertension.

Authors:  Sandra M Herrmann; Stephen C Textor
Journal:  Endocrinol Metab Clin North Am       Date:  2019-09-19       Impact factor: 4.741

10.  Effect of glomerular filtration rate and proteinuria on medical cost among screened subjects.

Authors:  Kunitoshi Iseki; Chiho Iseki; Issei Kurahashi; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.